ArticleNPJ cardiovascular health2026
Network meta-analysis to compare the efficacies of three surgical techniques in rheumatic mitral valve disease.
Article in NPJ cardiovascular health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review compared the efficacies of percutaneous mitral balloon commissurotomy (PMBC), mitral valvuloplasty (MVP), and mitral valve replacement (MVR) in patients with rheumatic mitral valve disease. Data from 15,271 patients across 23 cohort studies and randomized controlled trials were analyzed. Based on the results of the network meta-analysis, MVP demonstrated a lower early mortality rate [odds ratio (OR), 0.71; 95% confidence interval (CI): 0.54-0.92], follow-up mortality rate (OR: 0.84; 95% CI: 0.72-0.99), and complication rate (OR: 0.75; 95% CI: 0.64-0.88) compared to MVR. The follow-up reoperation rate in the MVP group was significantly lower than that in the PMBC group (OR: 0.49; 95% CI: 0.30-0.80). The optimal surgical strategy should be tailored to achieve better prognoses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.